Viking Therapeutics Raises $12.5M In PIPE

San Diego-based biopharmaceutiacls developer Viking Therapeutics says it has raised $12.5M in a common stock purchase agreement, from Aspire Capital Fund. The company, which is publicly traded on the NASDAQ as VKTX, said the initial purchase came at $1.50 per share, with the remaining $12M to be purchase over the next 30 months at prices based on the market price. Viking Therapeutics is developing treatments for metabolic and endocrine disorders.